← All trials
NCT03505528
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2017
- Primary completion
- Feb 28, 2019
- Completion date
- May 20, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EpiAxis TherapeuticsLead sponsor
- Australian National UniversityCollaborator
- Government of AustraliaOverall official - principal investigator
- Southern Medical Day Care CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.